The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 07, 2021

Filed:

Dec. 13, 2016
Applicants:

The Broad Institute, Inc., Cambridge, MA (US);

Dana-farber Cancer Institute, Inc., Cambridge, MA (US);

Inventors:

David K. Thomas, Boston, MA (US);

Todd R. Golub, Cambridge, MA (US);

Assignees:

THE BROAD INSTITUTE, INC., Cambridge, MA (US);

DANA-FARBER CANCER INSTITUTE, INC., Cambridge, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/48 (2006.01); G01N 31/00 (2006.01); C07K 16/28 (2006.01); G16C 20/00 (2019.01); G16C 10/00 (2019.01); G16C 20/64 (2019.01); G16C 20/50 (2019.01); G16C 20/20 (2019.01); G16C 20/62 (2019.01); G16C 20/60 (2019.01); A61P 9/10 (2006.01); A61P 9/04 (2006.01); A61K 39/00 (2006.01); A61K 38/17 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61P 9/04 (2018.01); A61P 9/10 (2018.01); G16C 10/00 (2019.02); G16C 20/00 (2019.02); G16C 20/20 (2019.02); G16C 20/50 (2019.02); G16C 20/60 (2019.02); G16C 20/62 (2019.02); G16C 20/64 (2019.02); A61K 38/1774 (2013.01); A61K 2039/505 (2013.01); C07K 2317/34 (2013.01);
Abstract

The invention provides compositions and methods for treating cardiac dysfunction, particularly cachexia-associated or RAGE-associated cardiac dysfunction, using an anti-RAGE agent. The invention also provides compositions and methods for identifying therapeutic agents useful for disrupting (slowing, reducing, reversing, or preventing). The methods comprise designing or identifying agents that bind to functional sites identified on the RAGE polypeptide, wherein binding of agents to the functional site(s) inhibit RAGE-mediated cachetogenic signaling.


Find Patent Forward Citations

Loading…